Japan's Shionogi says COVID-19 pill shows rapid clearance of virus


Pedestrians wearing protective face masks, amid the coronavirus disease (COVID-19) pandemic, walk at a shopping district on the first day after the lifting of COVID-19 restrictions imposed on Tokyo and 17 other prefectures, in Tokyo, Japan, March 22, 2022. REUTERS/Kim Kyung-Hoon

TOKYO (Reuters) - An experimental treatment from Shionogi & Co Ltd has shown rapid clearance of the virus that causes COVID-19, according to new data, the Japanese drug maker said on Sunday.

The pill, S-217622, "demonstrated rapid clearance of the infectious SARS-CoV-2 virus", Shionogi said in a statement, citing Phase-2b results from the Phase II/III clinical trial of the drug.

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read